713. Vancomycin Heteroresistance in Coagulase Negative Staphylococci (CoNS) Causing Central Line Associated Bloodstream Infection (CLABSI) in Pediatric Patients With Leukemia
Session: Poster Abstract Session: Resistance Mechanisms: Gram-Positive
Thursday, October 4, 2018
Room: S Poster Hall
Posters
  • 2nd proof 9-26-18 ID conference 2018 JW edits_FINAL.pdf (5.1 MB)
  • Background: Heteroresistance to vancomycin in Staphylococcus aureus may be associated with poor response to therapy. Although CoNS are the most important CLABSI pathogens in children with leukemia, and treatment failure is common, little is known about the frequency or clinical significance of heteroresistance. This is a retrospective study to evaluate frequency, risk factors and clinical impact of heteroresistance in CoNS CLABSI in immunocompromised children.

    Methods: The study was approved by the Institutional Review Board. All patients undergoing treatment for leukemia at St. Jude Children’s Research Hospital with CoNS isolated from blood between 2010 and 2016 were eligible. The first available isolate from each blood culture episode was obtained from the clinical laboratory and tested for vancomycin heteroresistance by population analysis profiling in comparison to the hVISA strain Mu3. Clinical data were collected from the medical record for up to 9 months after the episode. Episodes with ≥2 positive cultures or a single positive culture from a single lumen CVC were classified as CLABSI. Outcomes of interest included Treatment Failure (death or relapse of infection) or Poor Response to vancomycin therapy (persistence of bacteremia ≥1 day after initiation of vancomycin or Treatment Failure). Logistic regression was used to test associations between heteroresistance and exposures, and cumulative incidence analyses were used to test the effect on outcomes.

    Results:

    A total of 74 CoNS isolates were obtained from 65 participants, 39 with ALL and 26 with AML; 25/74 (33.8%) of isolates showed showed heteroresistance. The strongest identified risk factor for infection with a heteroresistant organism was number of days of vancomycin in the preceding 60 days (OR=1.05/day; P=0.035). In the 40 CLABSI episodes, heteroresistant isolates had a higher cumulative incidence of Poor Response and of Treatment Failure (P=0.006 and P=0.003 respectively).

    Conclusion:

    Vancomycin heteroresistance is common in CoNS causing CLABSI in children undergoing treatment for leukemia, and is associated with an increased risk of Treatment Failure. Further research should aim to validate this finding in an independent cohort and identify strategies to improve the diagnosis and treatment of these infections.

    Tina Dao, BS1, Joshua Parsons, PhD1, Randall Hayden, MD2, Jeffrey Rubnitz, MD PhD2, Joshua Wolf, MBBS FRACP2 and Jason Rosch, PhD1, (1)Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, (2)St. Jude Children's Research Hospital, Memphis, TN

    Disclosures:

    T. Dao, None

    J. Parsons, None

    R. Hayden, Roche Molecular: Scientific Advisor , Consulting fee . Abbott Molecular: Scientific Advisor , Consulting fee . Quidel: Scientific Advisor , Consulting fee .

    J. Rubnitz, None

    J. Wolf, Karius Inc.: Investigator , Research support .

    J. Rosch, None

    << Previous Abstract | Next Abstract

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.